Elucidating Kisspeptin Physiology by Blocking Kisspeptin Signaling
Primary Purpose
Hypogonadotropic Hypogonadism, Healthy Postmenopausal Women, Agonadism
Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
kisspeptin 112-121
GnRH
Sponsored by
About this trial
This is an interventional other trial for Hypogonadotropic Hypogonadism
Eligibility Criteria
A. Healthy Subjects
All healthy subjects will meet the following criteria:
- normal puberty with respect to onset and pace,
- no difficulty with blood draws,
- no prescription medications for at least 2 months with the exception of asthma medication (albuterol only), hypercholesterolemia medication and psychiatric medication,
- no illicit drug use or excessive alcohol consumption (>10 drinks/week),
- no history of a medication reaction requiring emergency medical care,
- normal physical exam and laboratory studies within protocol reference ranges.
Additional criteria based on subject population:
Healthy Men:
- between 21 and 40 years old,
- normal erectile and ejaculatory function, no history of reproductive disorders,
- testicular volume >15 ml.
Healthy women:
- between 21 and 40 years old,
- not breastfeeding or pregnant,
- menstrual cycles between 25 and 35 days in duration with no more than 5 days variability in cycle duration,
- no evidence for androgen excess (hirsutism or acne),
Healthy postmenopausal women:
- between 48 and 60 years old,
- no menstrual periods within the last year,
- previous history of menstrual cycles between 25 and 35 days in duration, with no more than 5 days variability in cycle duration,
- if applicable, able to undergo washout from hormone therapy,
- no evidence for androgen excess (hirsutism or acne),
- negative screening for Factor V Leiden for those who might receive estradiol treatment as a part of this study.
B. Subjects with Reproductive Disorders
All subjects with reproductive disorders will meet the following criteria:
- all medical conditions stable and well controlled, medications allowed include asthma medication (albuterol only), hypercholesterolemia medication and psychiatric medication,
- no medications known to affect reproductive endocrine function for at least 2 months except for medications used to treat the subject's reproductive condition,
- no history of a medication reaction requiring emergency medical care,
- no illicit drug use or excessive alcohol consumption (>10 drinks/week),
- for women, not breastfeeding or pregnant,
- if applicable, able to undergo appropriate washout from hormone therapy,
- normal physical exam and laboratory studies within protocol reference ranges,
Additional criteria based on subject population:
Men and women with hypogonadotropic hypogonadism,
- 18 years or older,
- Confirmed diagnosis by low sex steroids in the setting of low or inappropriately normal gonadotropins,
- If needed, additional labs and imaging tests may be performed.
Agonadal men,
- Between 18 and 60 years old.
Sites / Locations
- Massachusetts General Hospital
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
kisspeptin, GnRH
Arm Description
24-hour continuous intravenous infusion of kisspeptin 112-121 (12.5-40 mcg/kg/h), single intravenous dose of kisspeptin 112-121 (0.313-13.19 mcg/kg), and single bolus of GnRH (gonadotropin-releasing hormone) (2.5-250 ng/kg)
Outcomes
Primary Outcome Measures
Average difference in Luteinizing Hormone (LH) concentration at the beginning and end of kisspeptin infusion
Secondary Outcome Measures
Average difference in testosterone concentration at the beginning and end of kisspeptin infusion (males)
Average difference in estradiol concentration at the beginning and end of kisspeptin infusion (females)
Full Information
NCT ID
NCT01438073
First Posted
August 24, 2011
Last Updated
July 7, 2022
Sponsor
Massachusetts General Hospital
1. Study Identification
Unique Protocol Identification Number
NCT01438073
Brief Title
Elucidating Kisspeptin Physiology by Blocking Kisspeptin Signaling
Official Title
Elucidating Kisspeptin Physiology by Blocking Kisspeptin Signaling
Study Type
Interventional
2. Study Status
Record Verification Date
July 2022
Overall Recruitment Status
Completed
Study Start Date
September 2011 (Actual)
Primary Completion Date
April 2016 (Actual)
Study Completion Date
April 2016 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Massachusetts General Hospital
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The investigators are looking for subjects to complete a study on the role of kisspeptin in the reproductive system. Kisspeptin is a naturally occurring hormone in humans that tells the body to produce other reproductive hormones. However, giving someone a continued amount of kisspeptin over a period of time can have the opposite effect and tell the body to, for a short time, stop making hormones needed for reproduction. By giving 24-hour infusions of kisspeptin, the investigators hope to learn more about the role kisspeptin has in the way bodies function normally and the role it has in conditions that affect the reproductive system.
Detailed Description
Please contact study staff for a detailed description.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypogonadotropic Hypogonadism, Healthy Postmenopausal Women, Agonadism
7. Study Design
Primary Purpose
Other
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
96 (Actual)
8. Arms, Groups, and Interventions
Arm Title
kisspeptin, GnRH
Arm Type
Experimental
Arm Description
24-hour continuous intravenous infusion of kisspeptin 112-121 (12.5-40 mcg/kg/h), single intravenous dose of kisspeptin 112-121 (0.313-13.19 mcg/kg), and single bolus of GnRH (gonadotropin-releasing hormone) (2.5-250 ng/kg)
Intervention Type
Drug
Intervention Name(s)
kisspeptin 112-121
Other Intervention Name(s)
metastin 45-54
Intervention Description
24-h continuous intravenous infusion of kisspeptin 112-121 (12.5-40 mcg/kg/h), single intravenous dose of kisspeptin 112-121 (0.313-13.19 mcg/kg)
Intervention Type
Drug
Intervention Name(s)
GnRH
Other Intervention Name(s)
gonadotropin-releasing hormone
Intervention Description
Single intravenous dose of GnRH (2.5-250 ng/kg)
Primary Outcome Measure Information:
Title
Average difference in Luteinizing Hormone (LH) concentration at the beginning and end of kisspeptin infusion
Time Frame
24 hours
Secondary Outcome Measure Information:
Title
Average difference in testosterone concentration at the beginning and end of kisspeptin infusion (males)
Time Frame
24 hours
Title
Average difference in estradiol concentration at the beginning and end of kisspeptin infusion (females)
Time Frame
24 hours
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
A. Healthy Subjects
All healthy subjects will meet the following criteria:
normal puberty with respect to onset and pace,
no difficulty with blood draws,
no prescription medications for at least 2 months with the exception of asthma medication (albuterol only), hypercholesterolemia medication and psychiatric medication,
no illicit drug use or excessive alcohol consumption (>10 drinks/week),
no history of a medication reaction requiring emergency medical care,
normal physical exam and laboratory studies within protocol reference ranges.
Additional criteria based on subject population:
Healthy Men:
between 21 and 40 years old,
normal erectile and ejaculatory function, no history of reproductive disorders,
testicular volume >15 ml.
Healthy women:
between 21 and 40 years old,
not breastfeeding or pregnant,
menstrual cycles between 25 and 35 days in duration with no more than 5 days variability in cycle duration,
no evidence for androgen excess (hirsutism or acne),
Healthy postmenopausal women:
between 48 and 60 years old,
no menstrual periods within the last year,
previous history of menstrual cycles between 25 and 35 days in duration, with no more than 5 days variability in cycle duration,
if applicable, able to undergo washout from hormone therapy,
no evidence for androgen excess (hirsutism or acne),
negative screening for Factor V Leiden for those who might receive estradiol treatment as a part of this study.
B. Subjects with Reproductive Disorders
All subjects with reproductive disorders will meet the following criteria:
all medical conditions stable and well controlled, medications allowed include asthma medication (albuterol only), hypercholesterolemia medication and psychiatric medication,
no medications known to affect reproductive endocrine function for at least 2 months except for medications used to treat the subject's reproductive condition,
no history of a medication reaction requiring emergency medical care,
no illicit drug use or excessive alcohol consumption (>10 drinks/week),
for women, not breastfeeding or pregnant,
if applicable, able to undergo appropriate washout from hormone therapy,
normal physical exam and laboratory studies within protocol reference ranges,
Additional criteria based on subject population:
Men and women with hypogonadotropic hypogonadism,
18 years or older,
Confirmed diagnosis by low sex steroids in the setting of low or inappropriately normal gonadotropins,
If needed, additional labs and imaging tests may be performed.
Agonadal men,
Between 18 and 60 years old.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Stephanie B Seminara, MD
Organizational Affiliation
Massachusetts General Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Massachusetts General Hospital
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02114
Country
United States
12. IPD Sharing Statement
Citations:
PubMed Identifier
28368443
Citation
Lippincott MF, Chan YM, Rivera Morales D, Seminara SB. Continuous Kisspeptin Administration in Postmenopausal Women: Impact of Estradiol on Luteinizing Hormone Secretion. J Clin Endocrinol Metab. 2017 Jun 1;102(6):2091-2099. doi: 10.1210/jc.2016-3952.
Results Reference
derived
Learn more about this trial
Elucidating Kisspeptin Physiology by Blocking Kisspeptin Signaling
We'll reach out to this number within 24 hrs